Medical Developments International Limited (MVP) AI Stock Analysis

• Market Cap: AU$79.99M
• Dividend Yield: N/A
• Average Volume (3M): 153.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 13.61%
• EPS Growth: -55.12%
• Country: AU
• Employees: 68
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 112,658,325
• 10 Day Avg. Volume: 170,559
• 30 Day Avg. Volume: 153,819
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.66
• Price Target Upside: -7.04% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: AU$0.50 ▼(-29.58% Downside)

The overall stock score is primarily influenced by significant financial challenges, including persistent losses and liquidity issues. Technical analysis offers mixed signals, with slight positive momentum but overall weak sentiment. The negative P/E ratio and absence of dividends also weigh on the valuation.

Medical Developments International Limited Business Overview & Revenue Model

Company Description

Medical Developments International Limited (MVP) is a global company specializing in the development, manufacture, and distribution of innovative medical technologies. MVP operates primarily in the healthcare sector, focusing on products that enhance patient care in areas such as pain management, respiratory support, and veterinary applications. The company's flagship offering is the Penthrox inhaler, a fast-acting pain relief solution widely used in emergency settings and minor surgical procedures. Additionally, MVP provides a range of respiratory devices and veterinary equipment, catering to both human and animal health needs.

How the Company Makes Money

Medical Developments International Limited generates revenue through the sale of its medical products across various markets. The primary revenue stream comes from the distribution of the Penthrox inhaler, which is in high demand in emergency medical settings due to its effectiveness and ease of use. The company also earns income from its respiratory and veterinary product lines, which are sold to healthcare facilities, clinics, and veterinary practices. MVP's earnings are further bolstered by strategic partnerships and distribution agreements that expand its market reach globally. The company may also engage in research and development collaborations, contributing to its revenue through the development of new and improved medical technologies.

Medical Developments International Limited Financial Statement Overview

Summary

Medical Developments International Limited faces significant financial challenges with persistent losses, negative profit margins, and liquidity issues. Despite a low leverage balance sheet, profitability and cash flow inadequacies indicate a need for improved cost management and operational efficiency.

Income Statement

The company's income statement reveals a concerning trend, with declining revenue and significant losses in recent years. The gross profit margin has been negative in past years, indicating cost management issues. Despite a slight revenue increase in 2024, net profit margins remain deeply negative. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement reflects financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, reflecting relatively low leverage, which provides some stability. However, the return on equity is negative due to consistent net losses. The equity ratio is reasonably strong, suggesting a solid base of equity relative to assets, but the trend of declining equity over recent years is concerning. Overall, the balance sheet shows some strengths in terms of low debt levels, but the negative equity returns highlight profitability issues.

Cash Flow

The cash flow statement indicates significant challenges, with negative operating and free cash flows consistently. The operating cash flow to net income ratio suggests poor cash conversion, and the free cash flow to net income ratio is also negative, highlighting cash flow inadequacies. While there was an improvement in free cash flow in 2024, the overall cash flow situation remains weak, pointing to liquidity concerns and reliance on external financing.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	33.15M	32.34M	21.94M	25.27M	22.54M
Gross Profit	24.37M	-2.52M	-3.06M	16.67M	13.74M
EBITDA	-29.45M	-4.28M	-12.86M	-11.11M	3.03M
Net Income	-40.99M	-5.61M	-12.41M	-12.56M	379.00K
Balance Sheet
Total Assets	59.16M	109.49M	101.36M	100.17M	94.85M
Cash, Cash Equivalents and Short-Term Investments	9.73M	24.66M	20.40M	36.28M	15.54M
Total Debt	2.29M	2.56M	2.81M	3.05M	3.36M
Total Liabilities	13.43M	28.17M	44.06M	31.87M	51.51M
Stockholders Equity	45.73M	81.31M	57.30M	68.30M	43.34M
Cash Flow
Free Cash Flow	-13.95M	-24.16M	-15.94M	-15.37M	-8.30M
Operating Cash Flow	-10.78M	-16.50M	-10.72M	-8.81M	601.00K
Investing Cash Flow	-3.17M	-7.67M	-5.21M	-6.56M	-8.90M
Financing Cash Flow	-807.00K	28.06M	142.00K	36.12M	-1.97M

Medical Developments International Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Positive. The current price of 0.71 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.61, and above the 200-day MA of 0.56, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 59.27 is Neutral, neither overbought nor oversold. The STOCH value of 88.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	62 Neutral	AU$46.36M	20.59	4.85%	―	5.76%	-79.76%
Sector *	50 Neutral	AU$2.58B	3.16	5.87%	2.68%	36.95%	13.61%
IDT	46 Neutral	AU$30.12M	―	-19.31%	―	72.25%	43.66%
MVP	45 Neutral	AU$79.99M	―	-45.40%	―	13.61%	-55.12%
AGH	41 Neutral	AU$17.75M	―	-218.38%	―	-14.30%	29.69%
BOD	39 Underperform	AU$4.26M	―		―	1.92%	97.62%

Medical Developments International Limited Corporate Events

Medical Developments International Achieves Positive Cash Flow and Expands Penthrox Market

Medical Developments International Limited reported a positive operating cash flow for the second half of FY25, with significant improvements in revenue and financial position. The company saw increased demand for Penthrox, particularly in Australian hospitals, and successfully transitioned its distribution in France and Switzerland to partners. Despite a slight decline in respiratory revenue due to seasonal factors, the overall financial performance was bolstered by higher pricing and volume growth. The company plans to continue investing in strategic initiatives to accelerate the adoption of Penthrox and improve operational efficiencies.

The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.71 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Issues New Performance Rights

Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Appoints New Director to Drive Strategic Growth

Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.